Lineage Cell Therapeutics, Inc. (LCTX): Cash & Equivalents
$40.79M
As of 2025-12-31
$37.35M
As of 2026-06-30
+53.2%
3-year compound annual growth
+4.6%
5-year compound annual growth
-0.3%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $40.79M | -10.9% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $45.79M | +29.2% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $35.44M | +212.1% | 2025-03-10, Balance as of period end |
| 2022-12-31 | $11.36M | -79.6% | 2024-03-07, Balance as of period end |
| 2021-12-31 | $55.74M | +71.1% | 2023-03-09, Balance as of period end |
| 2020-12-31 | $32.59M | +243.1% | 2022-03-10, Balance as of period end |
| 2019-12-31 | $9.50M | -59.7% | 2021-03-11, Balance as of period end |
| 2018-12-31 | $23.59M | -36.0% | 2020-03-12, Balance as of period end |
| 2017-12-31 | $36.84M | +66.8% | 2019-03-14, Balance as of period end |
| 2016-12-31 | $22.09M | -47.7% | 2018-03-15, Balance as of period end |
| 2015-12-31 | $42.23M | +43.2% | 2018-03-15, Balance as of period end |
| 2014-12-31 | $29.49M | +436.5% | 2017-03-16, Balance as of period end |
| 2013-12-31 | $5.50M | +26.3% | 2016-03-15, Balance as of period end |
| 2012-12-31 | $4.35M | -80.4% | 2015-03-11, Balance as of period end |
| 2011-12-31 | $22.21M | -33.3% | 2014-03-17, Balance as of period end |
| 2010-12-31 | $33.32M | +173.4% | 2013-03-18, Balance as of period end |
| 2009-12-31 | $12.19M | n/a | 2012-03-14, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $40.79M | -10.9% |
| Relay Therapeutics, Inc. (RLAY) | 2025-12-31 | $84.02M | -32.4% |
| Pelthos Therapeutics Inc. (PTHS) | 2025-12-31 | $17.97M | n/m |
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | $12.36M | -24.1% |
| LENZ Therapeutics, Inc. (LENZ) | 2025-12-31 | $25.18M | +24.9% |
| TScan Therapeutics, Inc. (TCRX) | 2025-12-31 | $152.41M | -14.7% |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | $66.05M | +36.0% |
| Alector, Inc. (ALEC) | 2025-12-31 | $65.80M | +99.3% |
| Taysha Gene Therapies, Inc. (TSHA) | 2025-12-31 | $319.77M | +130.0% |
Compare LCTX, RLAY, PTHS, CRBU side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗